AKT1 and liver cancer: To confirm our hypothesis, we employed immunoblotting analysis and found the combined treatment of Lenvatinib and Pulrodemstat drastically blunted activation of PI3K-AKT signaling cascade in comparison with control or Lenvatinib monotherapy in both liver cancer cell lines as shown by decreased the phosphorylation levels of PI3K and AKT (Fig. 4A, B).